Analyzing Nuvectra (NVTR) and Its Rivals

Nuvectra (NASDAQ: NVTR) is one of 104 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Nuvectra to similar businesses based on the strength of its risk, earnings, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Insider & Institutional Ownership

How to Become a New Pot Stock Millionaire

46.9% of Nuvectra shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 3.6% of Nuvectra shares are owned by company insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Nuvectra and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nuvectra $31.84 million -$44.60 million -3.17
Nuvectra Competitors $1.54 billion $111.80 million -143.19

Nuvectra’s rivals have higher revenue and earnings than Nuvectra. Nuvectra is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Nuvectra and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvectra 0 0 4 0 3.00
Nuvectra Competitors 492 1881 3745 115 2.56

Nuvectra presently has a consensus target price of $12.00, suggesting a potential downside of 10.38%. As a group, “Surgical & medical instruments” companies have a potential upside of 10.99%. Given Nuvectra’s rivals higher possible upside, analysts plainly believe Nuvectra has less favorable growth aspects than its rivals.

Volatility & Risk

Nuvectra has a beta of -2.28, indicating that its stock price is 328% less volatile than the S&P 500. Comparatively, Nuvectra’s rivals have a beta of 0.80, indicating that their average stock price is 20% less volatile than the S&P 500.


This table compares Nuvectra and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nuvectra -140.09% -72.64% -46.96%
Nuvectra Competitors -62.26% -47.35% -18.28%


Nuvectra rivals beat Nuvectra on 10 of the 13 factors compared.

About Nuvectra

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company’s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with's FREE daily email newsletter.

Leave a Reply